National Health (Price and Special Patient Contribution) Amendment Determination 2018 (No. 6) (PB 73 of 2018) (Cth)
PB 73 of 2018
National Health (Price and Special Patient Contribution) Amendment Determination 2018 (No. 6)
National Health Act 1953
___________________________________________________________________________
I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.
Dated 27 July 2018
LISA LA RANCE
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
_________________________________________________________________________
Name of Instrument
(1)This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2018 (No. 6).
(2)This Instrument may also be cited as PB 73 of 2018.
Commencement
This Instrument commences on 1 August 2018.
Amendment of National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)
Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).
Schedule 1 Amendments
Schedule 1, entry for Ciprofloxacin in the form Tablet 500 mg (as hydrochloride)
omit from the column headed “Claimed Price”: 8.08 substitute: 10.08
Schedule 1, omit entry for Clindamycin
Schedule 1, entry for Codeine with Paracetamol
omit from the column headed “Form”: Tablet containing codeine phosphate 30 mg with paracetamol 500 mg
substitute: Tablet containing codeine phosphate hemihydrate 30 mg with paracetamol 500 mg
Schedule 1, entry for Dexamethasone with Framycetin and Gramicidin
omit from the column headed “Claimed Price”: 4.39 substitute: 5.09
Schedule 1, entry for Diphenoxylate with Atropine
omit from the column headed “Form”: Tablet containing diphenoxylate hydrochloride 2.5 mg with atropine sulfate 25 micrograms
substitute: Tablet containing diphenoxylate hydrochloride 2.5 mg with atropine sulfate monohydrate 25 micrograms
Schedule 1, entry for Doxepin in the form Capsule 10 mg (as hydrochloride)
omit from the column headed “Claimed Price”: 8.55 substitute: 9.96
Schedule 1, entry for Doxepin in the form Capsule 25 mg (as hydrochloride)
omit from the column headed “Claimed Price”: 9.43 substitute: 10.84
Schedule 1, entry for Doxycycline
(a) omit from the column headed “Form”: Capsule 100 mg (as hydrochloride) (containing enteric coated pellets)
substitute: Capsule 100 mg (as hyclate) (containing enteric coated pellets)
(b) omit from the column headed “Form”: Capsule 50 mg (as hydrochloride) (containing enteric coated pellets)
substitute: Capsule 50 mg (as hyclate) (containing enteric coated pellets)
Schedule 1, entry for Duloxetine in the form Capsule 30 mg (as hydrochloride)
omit from the column headed “Claimed Price”: 5.63 substitute: 11.30
Schedule 1, entry for Duloxetine in the form Capsule 60 mg (as hydrochloride)
omit from the column headed “Claimed Price”: 7.28 substitute: 12.95
Schedule 1, after entry for Escitalopram in the form Tablet 20 mg (as oxalate)
insert:
| Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexium | 30 | 5.87 | 9.20 |
| Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexium | 30 | 9.97 | 13.30 | |
| Esomeprazole and clarithromycin and amoxicillin | Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) | Oral | Nexium Hp7 | 1 | 23.65 | 26.98 |
Schedule 1, entry for Furosemide in the form Tablet 20 mg
omit from the column headed “Claimed Price”: 1.46 substitute: 1.90
Schedule 1, entry for Furosemide in the form Tablet 40 mg
omit from the column headed “Claimed Price”: 3.28 substitute: 3.79
Schedule 1, after entry for Hypromellose with Dextran
insert:
| Ibuprofen | Tablet 400 mg | Oral | Brufen | 30 | 1.79 | 4.11 |
Schedule 1, entry for Ipratropium
(a) omit from the column headed “Form”: Nebuliser solution containing ipratropium bromide 250 micrograms (anhydrous) in 1 mL single dose units, 30
substitute: Nebuliser solution containing ipratropium bromide 250 micrograms (as monohydrate) in 1 mL single units, 30
(b) omit from the column headed “Form”: Nebuliser solution containing ipratropium bromide 500 micrograms (anhydrous) in 1 mL single dose units, 30
substitute: Nebuliser solution containing ipratropium bromide 500 micrograms (as monohydrate) in 1 mL single units, 30
Schedule 1, entry for Irbesartan in the form Tablet 75 mg
omit from the column headed “Claimed Price” (all brands): 2.97 substitute: 3.66
Schedule 1, entry for Irbesartan in the form Tablet 150 mg
omit from the column headed “Claimed Price” (all brands): 3.48 substitute: 4.18
Schedule 1, entry for Irbesartan in the form Tablet 300 mg
omit from the column headed “Claimed Price” (all brands): 5.20 substitute: 5.90
Schedule 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 150 mg-12.5 mg
omit from the column headed “Claimed Price” (all brands): 3.73 substitute: 4.43
Schedule 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-12.5 mg
omit from the column headed “Claimed Price” (all brands): 5.37 substitute: 6.06
Schedule 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-25 mg
omit from the column headed “Claimed Price” (all brands): 5.68 substitute: 6.38
Schedule 1, entry for Lansoprazole in the form Tablet 15 mg (orally disintegrating)
omit from the column headed “Claimed Price”: 6.62 substitute: 7.39
Schedule 1, entry for Lansoprazole in the form Tablet 30 mg (orally disintegrating)
omit from the column headed “Claimed Price”: 8.95 substitute: 9.71
Schedule 1, entry for Levodopa with Carbidopa
omit from the column headed “Form”: Tablet 100 mg-25 mg (anhydrous)
substitute: Tablet 100 mg-25 mg (as monohydrate)
Schedule 1, entry for Methyldopa
omit from the column headed “Form”: Tablet 250 mg
substitute: Tablet 250 mg (as sesquihydrate)
Schedule 1, entry for Metoclopramide
omit from the column headed “Form”: Tablet containing metoclopramide hydrochloride 10 mg
substitute: Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate)
Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 20 mg
omit from the column headed “Claimed Price”: 8.10 substitute: 8.88
Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg
omit from the column headed “Claimed Price”: 14.41 substitute: 15.20
Schedule 1, after entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg
insert:
| Olmesartan with hydrochlorothizide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | Olmetec Plus | 30 | 7.07 | 8.93 |
| Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | Oral | Olmetec Plus | 30 | 13.38 | 15.24 | |
| Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | Oral | Olmetec Plus | 30 | 14.81 | 16.67 |
Schedule 1, after entry for Ranitidine in the form Tablet, effervescent, 150 mg (as hydrochloride)
insert:
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | Crestor | 30 | 3.50 | 5.50 |
| Tablet 10 mg (as calcium) | Oral | Crestor | 30 | 5.14 | 7.14 | |
| Tablet 20 mg (as calcium) | Oral | Crestor | 30 | 7.31 | 9.31 | |
| Tablet 40 mg (as calcium) | Oral | Crestor | 30 | 10.43 | 13.33 |
Schedule 1, entry for Roxithromycin in each of the forms: Tablet 150 mg; and Tablet 300 mg
omit from the column headed “Claimed Price”: 3.81 substitute: 4.45
0
0
0